Dossier
Apnimed Inc.
Coverage of Apnimed Inc. in the Nexus archive.
- Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range. The company is backed by Shionogi.
- Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering. The company is backed by Shionogi.